CClinicalTrials.gg
CompletedNCT02464800Updated Jun 8, 2015

Efficacy of Higher Cutting Rate in Microincision Vitrectomy for Proliferative Diabetic Retinopathy

An observational study in Proliferative Diabetic Retinopathy, sponsored by Kyorin University. Completed at 1 site in Japan. Open to participants aged 20 Years to 90 Years. Per ClinicalTrials.gov, last updated 2015-06-08.

Sponsored by Kyorin University · Observational

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
326
Ages
20 Years to 90 Years
Sex
All
01

Study summary

The medical records of 393 eyes of 326 patients with severe proliferative diabetic retinopathy were reviewed. Higher cutting rate instruments (5000 cut per minute) were used in 174 eyes and conventional instruments in 219 eyes (2500 cut per minute). The visual outcome and incidences of intraoperative and postoperative complications were compared.

02

Conditions studied

  • Proliferative Diabetic Retinopathy

Keywords

  • diabetic retinopathy
03

In context

Retinal Diseases

815 studies on the registry are indexed under Retinal Diseases; 105 are open to participants now.

This study's enrollment of 326 is above the median of 180 across 282 observational studies indexed under Retinal Diseases.

Browse Retinal Diseases studies →

Lead sponsor

Kyorin University is the lead sponsor of 33 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The patients who underwent 25-gauge vitrectomy for proliferative diabetic retinopathy with higher cutting rate instruments or conventional instruments

Inclusion criteria

  • The inclusion criteria were patients who had persistent vitreous hemorrhage, fibrovascular proliferation affecting the macula, or tractional RD and who had a follow-up for more than 6 months.

Exclusion criteria

Exclusion Criteria:

  • The eyes with follow-up less than 6 months
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
326 participants (actual)
Patient registry
No

Groups and cohorts

  • Higher cutting rate group

    Vitrectomy with higher cutting rate instruments (5000 cut per minute) were performed in 174 eyes for proliferative diabetic retinopathy

    Procedure: Vitrectomy for proliferative diabetic retinopathy

  • Conventional cutting rate group

    Vitrectomy with conventional instruments (2500 cut per minute) were performed in 219 eyes for proliferative diabetic retinopathy

    Procedure: Vitrectomy for proliferative diabetic retinopathy

Interventions

  • ProcedureVitrectomy for proliferative diabetic retinopathy

    25-gauge vitrectomy

06

What researchers measure

Primary outcomes

  1. Visual acuity

    Time frame: 6 months

Secondary outcomes

  1. Retinal reattachment

    Time frame: 6 months

07

Study locations

1 site
  • Makoto Inoue
    Mitaka, Tokyo 181-8611, Japan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 8, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02464800
Lead sponsor
Kyorin University
Responsible party
Makoto Inoue (Kyorin Eye center, Kyorin University) — Principal investigator
First posted
Jun 8, 2015
Start date
Apr 2007
Primary completion
Mar 2014
Completion
Mar 2015
Last update
Jun 8, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion